Pancreatic Cancer Research

ResearcherThe Cancer Institute HospitalActive in the last 2 years

Takeshi Okamoto

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0001-9719-0282; OpenAlex author ID A5003171350, A5125528739. Sources: OpenAlex.

Their work

Papers
26 (first author 1, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
24
Papers, trials and grants by year

2021: 2 papers · 2022: 6 papers · 2023: 7 papers · 2024: 2 papers · 2025: 4 papers · 2026: 5 papers

Papers 26

  1. Endoscopic Retrograde Cholangiopancreatography-guided Biliary Drainage with Duckbill-type Anti-reflux Metal Stent versus Endoscopic Ultrasound-guided Hepaticog… Co-author DOI 10.1002/deo2.70154↗
  2. Relative Dose Intensity and Outcomes in Elderly Patients With Resectable Pancreatic Cancer Receiving Neoadjuvant Chemotherapy. Co-author DOI 10.1002/jhbp.70058↗
  3. Changing treatment outcomes in metastatic and recurrent pancreatic cancer: a real-world comparison before and after the availability of nanoliposomal irinoteca… Co-author DOI 10.1093/jjco/hyaf194↗
  4. Gastrointestinal Bleeding after Particle Radiotherapy for Pancreatic Cancer. Co-author DOI 10.1159/000550483↗
  5. Patient-derived orthotopic xenograft models recapitulate the peritoneal dissemination of pancreatic cancer and delineate its transcriptional and regulatory pro… Co-author DOI 10.1186/s13046-026-03668-9↗
  6. Outcomes of multi-hole self-expandable metal stents versus fully covered self-expandable metal stents for malignant distal biliary obstruction in unresectable … Co-author DOI 10.1002/deo2.70014↗
  7. Impact of second-line combination chemotherapy on post-progression survival in metastatic and recurrent pancreatic cancer. Co-author DOI 10.1007/s10147-025-02796-0↗
  8. Clinical predictors of KRAS mutation detection in liquid biopsies for pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.pan.2025.06.013↗
  9. Efficacy of Anamorelin in Advanced Pancreatic Cancer Patients with a Poor Performance Status. Co-author DOI 10.2169/internalmedicine.3577-24↗
  10. Outcomes of 6-mm diameter fully covered self-expandable metal stents for preoperative biliary drainage in pancreatic cancer. Co-author DOI 10.1002/deo2.360↗
  11. Bone loss over time and risk of osteoporosis in advanced pancreatic cancer. Co-author DOI 10.1093/jjco/hyae028↗
  12. The efficacy and safety of a duckbill-type anti-reflux metal stent as the initial metal stent for distal malignant biliary obstruction in unresectable pancreat… Co-author DOI 10.1002/deo2.205↗
  13. Outcomes of pancreatic cancer with liver oligometastasis. Co-author DOI 10.1002/jhbp.1184↗
  14. Long-term outcomes of duckbill-type anti-reflux metal stents versus conventional covered metal stents in reinterventions after covered biliary metal stent dysf… Co-author DOI 10.1007/s00464-022-09836-0↗
  15. Prognostic impact of osteosarcopenia in patients with advanced pancreatic cancer receiving gemcitabine plus nab-paclitaxel. Co-author DOI 10.1016/j.pan.2023.02.002↗
  16. Outcomes of lung oligometastasis in pancreatic cancer. Co-author DOI 10.1093/jjco/hyad111↗
  17. Impact of the Extent of Weight Loss before Administration on the Efficacy of Anamorelin in Advanced Pancreatic Cancer Patients with Cachexia. Co-author DOI 10.2169/internalmedicine.0730-22↗
  18. Treatment Outcomes and Prognostic Factors of Gemcitabine Plus Nab-Paclitaxel as Second-Line Chemotherapy after Modified FOLFIRINOX in Unresectable Pancreatic C… Co-author DOI 10.3390/cancers15020358↗
  19. Early-onset pancreatic cancer: Clinical characteristics and survival outcomes. Co-author DOI 10.1016/j.pan.2022.04.003↗
  20. Treatment outcomes of nanoliposomal irinotecan as second-line chemotherapy after gemcitabine and nab-paclitaxel in metastatic and recurrent pancreatic cancer. Co-author DOI 10.1093/jjco/hyac145↗
  21. Impact of the COVID-19 Pandemic on the Management and End-of-life Care of Unresectable Pancreatic Cancer. Co-author DOI 10.2169/internalmedicine.0492-22↗
  22. Multiple Gastric Metastases after Distal Pancreatectomy for Pancreatic Cancer. Co-author DOI 10.2169/internalmedicine.8848-21↗
  23. CA19-9 Reduction After 4 Months of Treatment Is a Prognostic Factor for Locally Advanced Pancreatic Cancer. Co-author DOI 10.21873/invivo.13024↗
  24. Molecular Features and Clinical Management of Hereditary Pancreatic Cancer Syndromes and Familial Pancreatic Cancer. First author DOI 10.3390/ijms23031205↗
  25. A case of necrotic enteritis during neoadjuvant chemotherapy with gemcitabine and S-1 for resectable pancreatic ductal adenocarcinoma. Co-author DOI 10.1007/s12328-021-01480-w↗
  26. Treatment outcomes of erlotinib plus gemcitabine as late-line chemotherapy in unresectable pancreatic cancer. Co-author DOI 10.1093/jjco/hyab091↗

Closest collaborators

The 24 strongest of 24 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Tsuyoshi Takeda · 26 shared papers, 2021–2026 · strength 4.88
  2. Masato Ozaka · 26 shared papers, 2021–2026 · strength 4.88
  3. Naoki Sasahira · 26 shared papers, 2021–2026 · strength 4.88
  4. Takafumi Mie · 25 shared papers, 2021–2026 · strength 4.71
  5. Takaaki Furukawa · 24 shared papers, 2021–2026 · strength 4.50
  6. Takashi Sasaki · 24 shared papers, 2021–2026 · strength 4.42
  7. Akiyoshi Kasuga · 18 shared papers, 2021–2025 · strength 2.87
  8. Masato Matsuyama · 14 shared papers, 2021–2023 · strength 2.08
  9. Yuto Yamada · 9 shared papers, 2021–2023 · strength 1.26
  10. Hiroki Nakagawa · 7 shared papers, 2022–2025 · strength 1.25
  11. Yukari Suzuki · 4 shared papers, 2025–2026 · strength 1.01
  12. Yu Takahashi · 6 shared papers, 2021–2026 · strength 1.00
  13. Yosuke Inoue · 3 shared papers, 2022–2026 · strength 0.60
  14. Jun Hamada · 2 shared papers, 2026 · strength 0.53
  15. Manabu Takamatsu · 3 shared papers, 2021–2026 · strength 0.47
  16. Reo Maruyama · 1 shared paper, 2026 · strength 0.22
  17. Takahisa Matsuda · 1 shared paper, 2024 · strength 0.21
  18. Akio Saiura · 1 shared paper, 2023 · strength 0.18
  19. Tsuyoshi Hamada · 1 shared paper, 2023 · strength 0.16
  20. Atsushi Oba · 1 shared paper, 2023 · strength 0.15
  21. Yosuke Inoue · 1 shared paper, 2023 · strength 0.15
  22. Akio Saiura · 1 shared paper, 2022 · strength 0.13
  23. Yuta Ushida · 1 shared paper, 2022 · strength 0.13
  24. Yoshihiro Ono · 1 shared paper, 2021 · strength 0.11

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.